News

DILIsym at the PSTC BSEP Webinar Series

PSTC BSEP Webinar Series – Current trends in BSEP inhibition and perturbation to bile acid homeostasis as mechanisms of drug-induced liver injury

In 2016, the Predictive Safety Testing Consortium (PSTC) organized a webinar series around inhibition of the bile salt export pump (BSEP) and subsequent perturbations to bile acid homeostasis as a mechanism of drug-induced liver injury. This was a six-part series with presentations by top researchers in the field on current research and clinical examples, in vitro and in vivo tools for identifying BSEP liabilities or bile acid perturbations, and future directions.

Drs. Brett Howell and Paul Watkins were speakers in the 6th session of the series, entitled, “Future direction and next steps”. Dr. Howell’s presentation, “Combining BSEP inhibition data with mathematical modeling to impact decisions in drug development” discussed key factors regulating the functional impact of BSEP inhibition (e.g., compound exposure kinetics, type of inhibition) and provided examples of how the DILI-sim Initiative is combining experimental techniques and mathematical modeling to inform questions around drugs with BSEP inhibition liabilities. Dr. Watkins’ presentation, “The future: how BSEP inhibition investigations will aid improved DILI predictions” provided an overall perspective on the interpretation of serum bile acid profiles in bile‑acid mediated DILI, including the application of DILIsym® to predict and improve the understanding of troglitazone DILI.

The link to the video presentations in the PSTC BSEP webinar series, including those by Dr. Howell and Dr. Watkins can be found below.

https://c-path.org/current-trends-in-bsep-inhibition-and-perturbation-to-bile-acid-homeostasis-as-mechanisms-of-drug-induced-liver-injury/